AstraZeneca entered into a definitive agreement to acquire Alexion Pharmaceuticals, Inc. in a transaction valued at $39 billion. The boards of directors of both companies have unanimously approved the acquisition. Subject to regulatory clearances and shareholder approval, the acquisition is expected to close 3Q21. AstraZeneca has a growing scientific presence in oncology, and in cardiovascular, renal and metabolism, and respiratory diseases, with a focus on organ protection. AstraZeneca has ...